南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

基于转录的AND逻辑荧光平台的分裂型孔雀石绿适配体:糖尿病合并阿尔茨海默病患者双重miRNA检测的新型方法

Split malachite green aptamer transcription-based AND logic fluorescent platform: A novel approach for dual-miRNA detection in diabetes mellitus complicated with Alzheimer's disease

Ji Chen, Lumiao Liao, Hongming Lu, Yuting Hu, Huilan Yang, Danping Zhu, Jinlin Wu, Xi Mei

Journal:MICROCHEMICAL JOURNAL

IF:5.2

DOI:10.1016/j.microc.2026.119722

PMID:

Published:2026-09-16

research field:即时检测生物分析化学神经退行性疾病分子诊断microRNA检测代谢紊乱

Abstract

An AND logic fluorescent chip is developed for dual-miRNA detection in diabetes mellitus with Alzheimer's disease. • Self-primer cyclic amplification and dual rolling circle amplification enable ultrasensitive miRNA analysis. • Split malachite green aptamer transcription allows label-free, catalytically amplified fluorescence signal generation. • The chip achieves 0.15 fM LOD for both miRNAs and excellent specificity against mismatched sequences. • Clinical serum analysis shows 87.5% sensitivity for DMAD diagnosis, outperforming single-miRNA RT-qPCR. Early diagnosis of Diabetes Mellitus complicated with Alzheimer's Disease (DMAD) remains a major clinical challenge, and reliable detection of multiple microRNA (miRNA) biomarkers holds great promise for improving diagnostic accuracy. Herein, we report a split malachite green (MG) aptamer transcription-based fluorescent platform that operates as an “AND” logic gate for simultaneous ultrasensitive detection of two DMAD-associated miRNAs, miRNA-34a and miRNA-132. The platform integrates self-primer cyclic amplification with surface-anchored dual rolling circle transcription (RCT). Only when both target miRNAs are present, a target-recycling process releases Y-shaped probes, which subsequently initiate dual RCT to produce long DNA products containing tandem repeats of split MG aptamer sequences. These two products assemble into an intact MG aptamer, catalytically generating a strong fluorescence signal. The assay achieves a limit of detection as low as 0.15 fM for both miRNAs, with excellent specificity against mismatched and non-target sequences. The platform exhibits high stability (recoveries of 94.1–99.5% in spiked serum) and good reproducibility (coefficients of variation of 4.12% and 5.32% at 100 fM and 10 pM, respectively). In 30 clinical serum samples, the method correlates strongly with RT-qPCR and distinguishes DMAD patients from healthy controls with 87.5% sensitivity, significantly outperforming single-miRNA

本文使用的Yeasen产品

购物车
客服
转染试用